Abstract
Background
The optimal timing of chemoradiotherapy (CRT) for patients with localized gastric cancer remains unclear. This study aimed to compare the survival outcomes between neoadjuvant and postoperative CRT for patients with gastric and gastroesophageal junction (GEJ) cancer.
Methods
This retrospective study analyzed 152 patients with gastric (42%) or GEJ (58%) adenocarcinoma who underwent definitive surgical resection and received either neoadjuvant or postoperative CRT between 2005 and 2017 at the authors’ institution. The primary end point of the study was overall survival (OS).
Results
The median follow-up period was 37.5 months. Neoadjuvant CRT was performed for 102 patients (67%) and postoperative CRT for 50 patients (33%). The patients who received neoadjuvant CRT were more likely to be male and to have a GEJ tumor, positive lymph nodes, and a higher clinical stage. The median radiotherapy (RT) dose was 50.4 Gy for neoadjuvant RT and 45.0 Gy for postoperative RT (p < 0.001). The neoadjuvant CRT group had a pathologic complete response (pCR) rate of 26% and a greater rate of R0 resection than the postoperative CRT group (95% vs. 76%; p = 0.002). Neoadjuvant versus postoperative CRT was associated with a lower rate of any grade 3+ toxicity (10% vs. 54%; p < 0.001). The multivariable analysis of OS showed lower hazards of death to be independently associated neoadjuvant versus postoperative CRT (hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.36–0.91; p = 0.020) and R0 resection (HR 0.50; 95% CI 0.27–0.90; p = 0.021).
Conclusions
Neoadjuvant CRT was associated with a longer OS, a higher rate of R0 resection, and a lower treatment-related toxicity than postoperative CRT. The findings suggest that neoadjuvant CRT is superior to postoperative CRT in the treatment of gastric and GEJ cancer.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.
D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16. https://doi.org/10.1097/01.sla.0000143245.28656.15.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30. https://doi.org/10.1056/NEJMoa010187.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531.
Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8. https://doi.org/10.1016/S1470-2045(15)00040-6.
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33. https://doi.org/10.1200/JCO.2011.36.7136.
Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. JCO. 2009;27:851–6. https://doi.org/10.1200/JCO.2008.17.0506.
Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. https://doi.org/10.1016/S0140-6736(11)61873-4.
Noh SH, Park SR, Yang H-K, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96. https://doi.org/10.1016/S1470-2045(14)70473-5.
Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73. https://doi.org/10.1200/JCO.2011.39.1953.
Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33:3130–6. https://doi.org/10.1200/JCO.2014.58.3930.
van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. https://doi.org/10.1056/NEJMoa1112088.
Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616–28. https://doi.org/10.1016/S1470-2045(18)30132-3.
Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80. https://doi.org/10.1200/JCO.2004.01.015.
Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237–44. https://doi.org/10.1200/JCO.2005.01.305.
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8. https://doi.org/10.1200/JCO.2006.06.4840.
Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183–90. https://doi.org/10.1016/j.ejca.2017.04.027.
Roth AD, Allal AS, Bründler M-A, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol. 2003;14:110–5. https://doi.org/10.1093/annonc/mdg023.
Fu T, Bu Z-D, Li Z-Y, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2015;15:322. https://doi.org/10.1186/s12885-015-1341-7.
Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC, and CCTG. Ann Surg Oncol. 2017;24:2252–8. https://doi.org/10.1245/s10434-017-5830-6.
Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)–report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42:929–34. https://doi.org/10.1016/s0360-3016(98)00280-6.
Park SH, Zang DY, Han B, et al. ARTIST 2: interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). JCO. 2019;37(15 Suppl):4001–4001. https://doi.org/10.1200/JCO.2019.37.15_suppl.4001.
Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol. 2005;12:981–7. https://doi.org/10.1245/ASO.2005.03.008.
Bilimoria KY, Talamonti MS, Wayne JD, et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg. 2008;143:671–8; discussion 678. https://doi.org/10.1001/archsurg.143.7.671.
Yin S, Wang P, Xu X, Tan Y, Huang J, Xu H. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. J Cancer. 2019;10:3094–101. https://doi.org/10.7150/jca.30456.
Saedi HS, Mansour-Ghanaei F, Joukar F, Shafaghi A, Shahidsales S, Atrkar-Roushan Z. Neoadjuvant chemoradiotherapy in non-cardia gastric cancer patients: does it improve survival? Asian Pac J Cancer Prev. 2014;15:8667–71. https://doi.org/10.7314/apjcp.2014.15.20.8667.
Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532. https://doi.org/10.1186/s12885-015-1529-x.
Reynolds J, Preston S, O’Neill B, et al. ICORG 10–14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017;17:401. https://doi.org/10.1186/s12885-017-3386-2.
Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503. https://doi.org/10.1186/s12885-016-2564-y.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Theodore S. Hong has served as a compensated consultant for Merck, Novocure, and Synthetic Biologics and serves as research support for Ipsen, BMS, Astra-Zeneca, Taiho, IntraOp, and Tesaro (GlaxoSmithKline). Sam J. Klempner has served as a compensated consultant for Merck, BMS, Eli Lilly, Natera, Astellas, Daiichi Sankyo, and Pieris Oncology and owns stock/equity in Turning Point Therapeutics, Inc. Aparna R. Parikh has received personal fees from Checkmate Pharma, Eli Lilly, Pfizer, Roche, C2I genomics, Research to Institution Puretech, PMV Pharma, Plexxicon, Takeda, BMS, and Novartis. David P. Ryan owns equity in Exact Sciences and Acworth Pharmaceuticals, has grant in SU2C, and serves as a publisher for Uptodate.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, D.W., Lee, G., Hong, T.S. et al. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol 29, 242–252 (2022). https://doi.org/10.1245/s10434-021-10666-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10666-y